CoronaryAtlas logo
CoronaryAtlas
Tissue inhibitor of metalloproteinases-1
Pathway / Fibrous-cap degradation & rupture

Tissue inhibitor of metalloproteinases-1

TIMP1protein

TIMP-1 inhibits MMP-driven fibrous-cap degradation and mediates ECM remodeling and cardiac fibrosis post-MI.

Pathway placement
Cascade stepFibrous-cap degradation & rupture
Confidencehigh
RationaleMMP inhibitor; regulates ECM remodeling pre- and post-MI; reflects vascular and cardiac fibrotic response.
Also acts inMyocardial injury
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000102265

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
68
C — confounder / Type-II
85
A — assay feasibility
68
E — evidence strength
33
T1DI (composite)
9
Specificity differential (R−C)-17.6
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(7)